Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients

NCT05673577 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Camrelizumab+cetuximab+chemotherapy

Sponsor

Fudan University